Latest 10-K annual reports

Knightscope's 2024 annual report highlights continued losses, strategic restructuring, and a focus on expanding its market presence in public safety technology.

High Wire Networks' 2024 annual report reveals continued losses despite a modest increase in revenue and strategic moves to divest and restructure operations.

NexPoint Diversified Real Estate Trust's 2024 10-K filing reveals a year of strategic shifts, including the NHT acquisition, amid mixed financial performance and plans for asset reallocation.

OmniQ Corp.'s 2024 revenues decreased by 9% to $73.6 million, with a net loss of $10 million, as the company focuses on operational excellence and strategic acquisitions.

LFTD Partners Inc.'s 10-K filing reveals recurring losses, regulatory challenges, and significant financial obligations, raising concerns about its ability to continue as a going concern.

Calidi Biotherapeutics outlines its capital structure, clinical trial progress, and regulatory landscape in its annual 10-K filing, highlighting both opportunities and challenges for its novel immuno-oncology platforms.

byNordic Acquisition Corporation's latest 10-K filing reveals delisting from Nasdaq, ongoing efforts to secure a business combination amidst financial constraints, and a looming deadline for liquidation.

Scientific Industries reports a decrease in net loss for fiscal year 2024, driven by cost reductions in its Bioprocessing Systems operations, while navigating challenges in its Benchtop Laboratory Equipment segment.

Nu-Med Plus, Inc. files its Form 10-K for the year ended December 31, 2024, reporting a net loss and highlighting substantial doubt about its ability to continue as a going concern without additional funding.

Interactive Strength Inc.'s 2024 10-K filing reveals ongoing operating losses and details strategic initiatives for future growth, including acquisitions and international expansion.

Xos Inc. faces substantial doubt about its ability to continue as a going concern despite reporting increased revenue and outlining cost-cutting measures in its annual report.

Mesa Royalty Trust's 2024 financial results reveal a significant decrease in royalty income primarily due to lower natural gas prices and production volumes.

Babcock & Wilcox's 10-K filing reveals substantial doubt about its ability to continue as a going concern, despite a higher backlog and strategic divestitures aimed at improving liquidity.

Vaso Corporation's 2024 annual report reveals a revenue increase of 7.1% to $86.8 million, but a decrease in net income due to higher operating expenses.

Newsmax Inc. reports a 26.4% increase in revenue for 2024, driven by growth in broadcasting and digital segments, alongside strategic investments in content and distribution.

Provident Bancorp's 2024 10-K filing reveals a strategic shift in loan portfolio composition amidst a challenging economic landscape, with a focus on traditional commercial real estate and a reduction in digital asset exposure.

Super League Enterprise reports a decrease in revenue for FY 2024 and addresses concerns about its ability to continue as a going concern.

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, details its financial performance for 2024 and outlines key developments in its clinical programs, including the initiation of a Phase 3 trial for ARD-101.

Dogwood Therapeutics' 2024 10-K filing highlights its focus on developing Halneuron for chemotherapy-induced neuropathic pain and antiviral therapies for fibromyalgia and Long-COVID, while addressing concerns about its ability to continue as a going concern.

Phio Pharmaceuticals Corp. files its 10-K report for the fiscal year ended December 31, 2024, detailing financial results and progress in its clinical-stage immuno-oncology programs, particularly the Phase 1b trial of PH-762.

Pathfinder Bancorp's net income decreased in 2024 due to increased credit loss provisions and noninterest expenses, despite growth in noninterest and net interest income.

First National Corporation's 2024 net income decreased due to merger-related expenses and increased provisions for credit losses, despite growth in loans and deposits following the acquisition of Touchstone Bankshares.

ADM Endeavors, Inc. reports an 11% increase in revenue and a significant rise in net income for the year ended December 31, 2024, driven by growth in the government entity segment.

Cartesian Growth Corporation II files its annual report on Form 10-K, highlighting its ongoing search for a business combination and expressing substantial doubt about its ability to continue as a going concern.

RetinalGenix Technologies Inc. outlines its strategy to prevent vision loss through innovative devices and drug development while acknowledging substantial financial challenges and a going concern uncertainty.

Traws Pharma's 2024 10-K reveals a year of transformation through a merger, pipeline advancement, and ongoing financial uncertainties.

Carisma Therapeutics halts research and development, explores strategic alternatives including asset sales, and prepares for a potential wind down to preserve cash.

Archimedes Tech SPAC Partners II Co. files its annual report on Form 10-K, detailing its business as a blank check company focused on technology acquisitions.

STRATS Trust for Allstate Corporation Securities, Series 2006-3 files its annual report on Form 10-K for the fiscal year ended December 31, 2024, with details on servicing compliance and related matters.

STRATS Trust for Goldman Sachs Securities, Series 2006-2, reports a material instance of noncompliance related to investor remittances in its annual 10-K filing.